Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.5652W HIGH $58.90
Volume
9.36 K
Value Traded
20.36 M
Short % Float
14.92%
+4.34%Week
-5.64%1 Month
+90.11%3 Month
+167.7%6 Month
+36.55%5 Year
+526.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.57 B
EPS (TTM)
-1.12
P/E Ratio
-
Ent. Value
3.44 B
Total Shares
70.80 M
Float Shares
21.05 M
Insiders
71.05%
Institutions
14.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PLSE Catalyst Timeline
Dated clinical, regulatory and corporate events for Pulse Biosciences, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pulse Biosciences, Inc
4Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 4
●R&D DayPresentation
Pulse Biosciences management to present at Canaccord Genuity 46th Annual Growth Conference
●Quarterly UpdateCorporate
Pulse Biosciences to report Q2 2026 business updates and financial results
▲Enrollment MilestoneTrial
NANOPULSE-AF Study surpasses enrollment midpoint
atrial fibrillationsource ↗
Past FDA Catalysts and PDUFA Decisions
How PLSE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Pulse Biosciences, Inc is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PLSE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nPulse Cardiac Catheter Ablation System | Atrial Fibrillation (AFib) | 2026-03-17 | 100% Procedural Success at 6 Months: 75/75 evaluable patients achieved acute Pulmonary Vein Isolation (PVI) success.; 96% Sustained Success at 12 Months: Long-term follow-up (45/47 patients) confirmed highly durable Pulmonary Vein Isolation (PVI), exceeding traditional expectations in a field where approximately 20-25% recurrence is common.; Industry-Leading Procedural Efficiency: Left Atrial Dwell Time: 21.0 ± 13.3 minutes, Total Procedure Time: Averaged 65 minutes, including only 9.8 minutes of fluoroscopy.; Safety Profile: A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint.Read More | Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical DataRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Teplitsky Liane RaeOfficer (Chief Operating Officer) | Buy | 1,001 4,095 held | $49.95 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLSE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.1 % | 1.08 M | 50.13 K |
PLSE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PLSE ranks across every disease it competes in
Competitive Position is a premium feature
See how PLSE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPLSE News
PLSE▲ +1.4%today
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Pulse Biosciences, Inc. announced that its nPulse technology will be featured at the 21st Annual International Ventricular Arrhythmias Symposium in 2026. The event will take place in New York on October 9-10, where preclinical applications of the nPulse prototypes will be presented. This highlights the company's ongoing innovation in the field of nanosecond pulsed field ablation.
Read more →PLSE▲ +1.4%today
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences has successfully reached its enrollment target of 164 patients for the NANOPULSE-AF pivotal clinical study. This study evaluates the nPulse Cardiac Catheter System for treating atrial fibrillation. The positive response from the electrophysiology community highlights the potential of the novel nano-PFA technology.
Read more →PLSEPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences has completed patient enrollment in the PRECISE-BTN clinical study, which evaluates the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The first patient has successfully completed their final 12-month follow-up visit, marking a significant milestone for the study.
Read more →PLSEPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. has granted equity inducement awards to two new employees under its 2017 Inducement Equity Incentive Plan. This move is part of their strategy to leverage their proprietary Nanosecond Pulsed Field Ablation technology. The awards were approved by the Compensation Committee of the Board of Directors.
Read more →PLSE▲ +10.9%on this news
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences, Inc. reported its second quarter financial results for 2026, highlighting a cash position of $101.6 million. The company successfully raised $46.8 million through an at-the-market program. These updates reflect the ongoing progress in leveraging its novel Nanosecond Pulsed Field Ablation technology.
Read more →PLSEPulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
Pulse Biosciences, Inc. will present at the Canaccord Genuity 46th Annual Growth Conference in Boston. The presentation is scheduled for August 11 at 2:30 pm ET. A live and recorded webcast will be accessible for attendees, enhancing the company's outreach and engagement with potential investors.
Read more →PLSEPulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Pulse Biosciences has announced that its NANOPULSE-AF IDE pivotal study has surpassed the enrollment midpoint, which was reached shortly after the study commenced in April 2026. The company expressed satisfaction with the strong enrollment trajectory, highlighting the enthusiasm from investigational sites. This progress is a positive indicator for the ongoing study.
Read more →PLSE▲ +8.3%on this news
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Pulse Biosciences, Inc. has announced that it will report its second quarter 2026 financial results on August 6, 2026. Following the report, the company will host a conference call to discuss the updates. This reflects the company's commitment to keeping investors informed about its business progress.
Read more →PLSEPulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. has announced its intention to redeem outstanding warrants. This move is part of the company's ongoing financial strategy. Further details regarding the implications of this redemption have not been disclosed in the announcement.
Read more →PLSEPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pulse Biosciences is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The event will provide an opportunity for the company to share insights and updates with investors and stakeholders. Further details regarding the presentation are currently not available.
Read more →PLSE▲ +22.1%on this news
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences' co-chairmen have made ATM equity purchases totaling around $13.3 million. This move indicates confidence in the company's future, although specific details regarding the implications of these purchases are not provided.
Read more →PLSEPulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences is scheduled to present at the BofA Securities 2026 Healthcare Conference. The details regarding the presentation content and timing have not been disclosed in the article. This conference is a significant event for healthcare companies to showcase their innovations and strategies.
Read more →PLSEPulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences has reported its business updates and financial results for the first quarter of 2026. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or business developments are not disclosed in the provided text.
Read more →PLSEPulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences showcased promising updated data regarding their nPulse™ Cardiac Catheter System at the Heart Rhythm 2026 event. The outcomes presented indicate significant advancements in cardiac care, emphasizing the system's efficacy. This presentation marks a crucial step in the company's ongoing commitment to improving patient outcomes in cardiology.
Read more →PLSEPulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences will showcase its nPulse™ technology at the Heart Rhythm Society 2026 Annual Meeting. This event is significant for the company as it highlights their innovative approach in the field of cardiac health. Further details about the technology's applications and benefits are anticipated during the meeting.
Read more →PLSE▲ +14.1%on this newsshared move
Pulse Biosciences to Host Analyst Event on April 25, 2026
Pulse Biosciences has announced an upcoming analyst event scheduled for April 25, 2026. Details regarding the event's agenda or topics have not been disclosed in the article. The announcement signifies the company's ongoing engagement with investors and analysts. Further information may be expected as the event date approaches.
Read more →PLSEPulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences has appointed Liane Teplitsky as Chief Operating Officer and expanded Dr. David Kenigsberg's role as Chief Medical Officer. This strategic move aims to enhance the company's focus on the development and commercialization of its nPulse Cardiac Catheter Ablation System. Teplitsky brings extensive experience in medical technology, while Kenigsberg's expanded role will support ongoing clinical studies.
Read more →About Pulse Biosciences, Inc
Headquarters3957 POINT EDEN WAY, HAYWARD, CA, 94545
BIOPHARMAWATCH ELITE PLUS
Trade the next PLSE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime